SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Switching from Brand‐Name to Generic Psychotropic Medications: A Literature Review
6 references·1 citing·18 second hop
Switching from Brand‐Name to Generic Psychotropic Medications: A Literature Review (2010)Switching from Brand‐Name to Generic Psyc…CLINICAL CONSEQUENCES OF GENERIC SUBSTITUTION OF LAMOTRIGINE FOR PATIENTS WITH EPILEPSY (2009)CLINICAL CONSEQUENCES OF GENE…Clinical Equivalence of Generic and Brand-Name Drugs Used in Cardiovascular Disease (2008)Clinical Equivalence of Gener…Clinical consequences of generic substitution of lamotrigine for patients with epilepsy (2008)Clinical consequences of gene…Compulsory Generic Switching of Antiepileptic Drugs: High Switchback Rates to Branded Compounds Compared with Other Drug Classes (2007)Compulsory Generic Switching …Are there potential problems with generic substitution of antiepileptic drugs? (2006)Are there potential problems …The bioequivalence and therapeutic efficacy of generic versus brand-name psychoative drugs (2003)The bioequivalence and therap…Potential Clinical and Economic Impact of Switching Branded Medications to Generics (2015)Potential Clinical and Econom…Statistical Methods for Meta-Analysis (1988)Assessing the quality of reports of randomized clinical trials: Is blinding necessary? (1996)Evaluating non-randomised intervention studies (2003)A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study (2013)Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending (2017)Assessment [RETIRED] (1990)Bioequivalence and other unresolved issues in generic drug substitution (2003)Generic substitution in the treatment of epilepsy: Patient and physician perceptions (2008)Therapeutic equivalency of generic antiepileptic drugs: results of a survey (2004)The risks and costs of multiple-generic substitution of topiramate (2009)Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century After the 1984 Waxman-Hatch Legislation (2010)Comparing Generic and Innovator Drugs: A Review of 12 Years of Bioequivalence Data from the United States Food and Drug Administration (2009)Patients’ Perceptions Of Generic Medications (2009)Assessing bioequivalence of generic antiepilepsy drugs (2011)Demand-side policies to encourage the use of generic medicines: an overview (2013)An evaluation of consumers’ knowledge, perceptions and attitudes regarding generic medicines in Auckland (2010)Evaluating pharmacists’ views, knowledge, and perception regarding generic medicines in New Zealand (2010)Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century after the 1984 Waxman-Hatch Legislation (2011)
this work references cited by second hop

References

  • 2008Clinical Equivalence of Generic and Brand-Name Drugs Used in Cardiovascular Disease432 cited
  • 2007Compulsory Generic Switching of Antiepileptic Drugs: High Switchback Rates to Branded Compounds Compared with Other Drug Classes177 cited
  • 2003The bioequivalence and therapeutic efficacy of generic versus brand-name psychoative drugs154 cited
  • 2006Are there potential problems with generic substitution of antiepileptic drugs?141 cited
  • 2008Clinical consequences of generic substitution of lamotrigine for patients with epilepsy117 cited
  • 2009CLINICAL CONSEQUENCES OF GENERIC SUBSTITUTION OF LAMOTRIGINE FOR PATIENTS WITH EPILEPSY95 cited

Cited by

  • 2015Potential Clinical and Economic Impact of Switching Branded Medications to Generics76 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work